secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001193125-22-265260
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

President of R&D Judith Dunn resigns; position eliminated; CEO assumes direct oversight
--------------------------------------------------------------------------------

- Dr. Judith Dunn resigns as president, R&D; separation agreement signed October 14, 2022.
- Dunn remains employed through Jan 3, 2023, then provides biotech consulting in transitional capacity.
- Clinical development organization now reports directly to CEO Bryan Stuart; president R&D role eliminated.
- Company continues search for Chief Medical Officer as previously announced.
- Extended 6-month exercise period for stock options post-separation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/0001193125-22-265260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/d327131d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-265260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer